BioNTech SE | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (25)

Latest Posts

About This Stock More About This Stock
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
Article By: ChinaBio® Today
Saturday, February 3, 2024 2:40 PM EST
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
In this article: SNY, HCM, BNTX, GRCL
Read
Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China
Article By: ChinaBio® Today
Saturday, January 27, 2024 1:40 PM EST
ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it aims to bring to the US market.
In this article: BNTX, SGMT, AVBP Also: ASCLF
Read
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Article By: ChinaBio® Today
Saturday, January 13, 2024 1:20 PM EST
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion.
In this article: GSK, JNJ, NVS, BAYRY, BNTX, PRAX, AMAM, HLVX Also: TAK
Read
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
Article By: ChinaBio® Today
Saturday, October 14, 2023 12:59 PM EST
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with potential value of more than $1 billion.
In this article: IMAB, KNTPF, ASPHF, SNY, BNTX Also: AZN, GSK
Read
Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement
Article By: ChinaBio® Today
Saturday, July 15, 2023 3:00 PM EST
Deals and financings, trials and approvals in the Chinese biotech/biopharma sphere.
In this article: BNTX, WXXWY
Read

Latest Tweets for $BNTX

No tweets yet!

PARTNER HEADLINES